| Naslov: | The efficacy, safety and tolerability of canakinumab in the treatment of familial Mediterranean fever : a systematic review of the literature |
|---|
| Avtorji: | Kačar, Mark (Avtor)
Savic, Sinisa (Avtor)
van der Hilst, Jeroen CH (Avtor) |
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.02 - Pregledni znanstveni članek |
|---|
| Organizacija: |  UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik |
|---|
| Povzetek: | Familial Mediterranean Fever (FMF) is the most prevalent genetic autoinflammatory disorder. In most patients, treatment with colchicine can prevent attacks of fever and inflammation. However, 5%-10% of patients are resistant to colchicine treatment, while a similar percentage cannot tolerate colchicine in doses needed to prevent attacks. For these patients, Canakinumab, a full human antibody against IL-1[beta], has been approved recently by the FDA and EMA. In this article, we present a systematic review of the long-term efficacy, safety, and tolerability of Canakinumab in FMF patients who cannot tolerate colchicine or who are resistant to colchicine treatment. |
|---|
| Ključne besede: | familial Mediterranean fever -- therapy -- review, amonoclonal antibodies, canakinumab, anti-IL1 therapy |
|---|
| Leto izida: | 2020 |
|---|
| Založnik: | Dove Press |
|---|
| Izvor: | Nova Zelandija |
|---|
| UDK: | 577.2 |
|---|
| ISSN pri članku: | 1178-7031 |
|---|
| COBISS_ID: | 58075139  |
|---|
| DOI: | 10.2147/JIR.S206204 |
|---|
| Opombe: | Nasl. z nasl. zaslona;
Opis vira z dne 1. 4. 2021;
|
|---|
| Število ogledov: | 3 |
|---|
| Število prenosov: | 1 |
|---|
| Datoteke: |  - Predstavitvena datoteka, prenos (481,07 KB)
|
|---|
| | | Nadgradivo: | J. inflamm. res.
Dove Medical Press
|
|---|
| | | Metapodatki: |     |
|---|
| Avtorske pravice: | © 2020 Kacar et al. |
|---|
|
:
|
|
|---|
| | |
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |